Loading...

Dermata Therapeutics, Inc.

DRMAW•NASDAQ
Healthcare
Biotechnology
$0.02
$0.00(0.57%)

Dermata Therapeutics, Inc. (DRMAW) Stock Overview

Explore Dermata Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.4/100

Key Financials

Market Cap112.9K
P/E Ratio-0.27
EPS (TTM)$-2.16
ROE-2.71%
Fundamental Analysis

AI Price Forecasts

1 Week$0.02
1 Month$0.02
3 Months$0.00
1 Year Target$0.00

DRMAW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Dermata Therapeutics, Inc. (DRMAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.27 and a market capitalization of 112.9K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for DRMAWStats details for DRMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DRMAWAnalyst Recommendations details for DRMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

CEO

Gerald T. Proehl

Employees

8

Headquarters

3525 Del Mar Heights Road, San Diego, CA

Founded

2021

Frequently Asked Questions

;